Stocks
Denali Therapeutics (DNLI) EBITDA margin US GAAP (year values) |
|||||||||
| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -769.1% | 21.2% | -590.1% | -304.6% | -54.4% | |||
| Changes by years, y/y, % | -739pp | +790pp | -611pp | +286pp | +250pp | +12.5% | |||
Denali Therapeutics. EBITDA margin, %
Denali Therapeutics. EBITDA margin, changes, pp
Denali Therapeutics (DNLI) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2022Q3 | FY2022Q4 | FY2023Q1 | FY2023Q2 | FY2023Q3 | LTM ? | |||
| EBITDA margin, % | ? | -2 960% | -984.7% | -315.2% | 58.7% | -8 806% | ||
| Changes by years, y/y, % | -1 382pp | -385pp | -162pp | +172pp | -5 847pp | |||
| Changes by quarters, q/q, % | -2 847pp | +1 975pp | +669pp | +374pp | -8 865pp | |||
